The GYG2 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used HEK293T human embryonic kidney epithelial cell line. These polyclonal cells harbor targeted disruption of the GYG2 gene, which encodes glycogenin-2, the priming enzyme required for de novo glycogen synthesis. By abolishing GYG2 function, this knockout model enables investigation of glycogen metabolism defects and the molecular pathology of glycogen storage disease type XV. The product is supplied as a polyclonal population, offering flexibility for cell-based assays without clonal selection.
The parental HEK293T cell line originates from human embryonic kidney and is a derivative of the HEK293 line that stably expresses the SV40 large T antigen. This feature confers high transfection efficiency and robust protein expression, making HEK293T an ideal host for transient and stable genetic manipulation. While not a primary metabolic cell type, HEK293T cells retain functional insulin and AMPK signaling cascades, providing a tractable system to dissect glycogen metabolism under controlled conditions. Their epithelial morphology and adherent growth facilitate imaging and biochemical assays.
Glycogenin-2 (GYG2) initiates glycogen biosynthesis by catalyzing the autoglycosylation of its own tyrosine 195 residue using UDP-glucose, generating a short ??-1,4-linked glucose oligosaccharide that serves as a primer for glycogen synthase (GYS2) to elongate glycogen chains. This priming step is indispensable for de novo glycogen formation in liver, heart, and other glycogen-storing tissues. GYG2 activity is acutely regulated by upstream signals including insulin and insulin-like growth factor 1 via AKT, as well as by AMPK and protein phosphatase 1 (PP1), which modulate glycogen synthase and phosphorylase. GYG2 physically interacts with glycogen synthase, glycogen branching enzyme (GBE1), and PP1 regulatory subunit 3 (PPP1R3) to form a multimeric glycogen synthesis complex. Downstream, GYG2 primes the synthesis of mature glycogen that is subsequently mobilized by glycogen phosphorylase (PYGL/PYGM) and debranching enzyme.
In HEK293T cells, ectopic expression or endogenous low-level glycogen metabolism may be rewired through GYG2 deletion, allowing researchers to dissect the role of glycogen priming in epithelial kidney-derived cells. Although GYG2 is predominantly expressed in liver and cardiac muscle, its knockout in HEK293T provides a simplified cellular environment to study insulin-stimulated glycogen synthesis, glucose uptake, and AMPK-mediated energy sensing without the confounding layers of tissue-specific isoforms. This model is particularly useful for screening small molecules that target GYG2 or its interacting partners, as well as for reconstitution experiments with mutant GYG2 variants linked to cardiomyopathy or glycogen storage disease.
The GYG2 Knockout HEK293T Polyclonal Cells are suitable for a range of functional and phenotypic assays. Glycogen content can be quantified via PAS staining or enzymatic glycogen assay, while glycogen synthase activity and glucose uptake assays assess metabolic flux. Insulin stimulation experiments combined with western blotting for AKT phosphorylation, glycogen synthase expression, and GYG2 levels validate pathway engagement. Co-immunoprecipitation of GYG2 with GYS2, GBE1, or PPP1R3 can map interaction networks. This knockout model supports drug screening for glycogen disorders, insulin signaling research, and CRISPR-based functional genomics. For further technical details and custom cell services, please contact Ascent Research.
